Industry

DUBLIN–(BUSINESS WIRE)–The “Generalized Myasthenia Gravis (gMG) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This ‘Generalized Myasthenia Gravis (gMG)- Epidemiology Forecast – 2032’ report delivers an in-depth understanding of Generalized Myasthenia Gravis (gMG) historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and … [Read more…]

– The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD (“SKATBT-A3”), which measures the effectiveness of the treatment on the patient’s overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. – The first efficacy trial using personalized TCM … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Clarify Health, a leading cloud analytics and value-based payments platform company, today announced the publication of new research on pediatric mental health in a brief titled, “The Kids Are Not Alright: Pediatric Mental Health Care Utilization from 2016 – 2021.” The research was conducted by the Clarify Health Institute, which is led by … [Read more…]

Clinical Expertise and Advanced Therapies Cater to Growing Patient Population Statewide COLUMBUS, Ohio & CLEVELAND–(BUSINESS WIRE)–#VirtisHealthAmbulatoryInfusionCenters—Virtis Health, an innovative, national provider dedicated to therapeutic and diagnostic services for patients with complex conditions requiring specialty infusible and injectable medications, announced today the unveiling of ambulatory infusion centers (AIC) in Columbus and Cleveland, Ohio. Virtis Health is … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the publication of preclinical data showing the effect of sodium phenylbutyrate (PB) and taurursodiol (TURSO, also known as ursodoxicoltaurine) on the transcriptomic and metabolomic profiles of primary skin fibroblasts from adults with sporadic amyotrophic lateral sclerosis (ALS) and adults without ALS. These … [Read more…]

The free program helps individuals become more care-prepared through information, resources, connections, counseling and support. MINNEAPOLIS–(BUSINESS WIRE)–As part of Sickle Cell Disease (SCD) Awareness Month in September, The National Marrow Donor Program® (NMDP)/Be The Match® is sharing the Sickle Cell Warrior Program, an initiative designed to eliminate barriers to equitable care, facilitate early referral and … [Read more…]

Poster presentations by Dr. Philip Lavin, a biostatistician for 80 FDA approvals/clearances, and Dr. József Tímár, Professor and Director of the Central Pathology Laboratory at Semmelweis University View the posters here: LINK VIENNA, Va.–(BUSINESS WIRE)–$CVM #ESMO22–CEL-SCI Corporation (NYSE American: CVM) today announced two poster presentations were delivered at the European Society for Medical Oncology (EMSO) … [Read more…]

NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry. “It is an honor and tremendous validation of our team and progress … [Read more…]

Hani Zeini is a 20+ year executive in the breast aesthetics industry, including as CEO and Founder of Sientra SANTA BARBARA, Calif.–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has retained Hani Zeini to an exclusive, … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Fierce15—Strand Therapeutics today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics. The … [Read more…]